Dr. Douglas Loe

Leede Financial Inc.

Douglas Loe, managing director and analyst at Leede Jones Gable, brings more than a decade of experience to financial analysis in the global drug development, medical technology, healthcare services and specialty pharmaceutical sectors. Loe has been recognized as one of Canada's top healthcare analysts by the StarMine Analysts Awards, based on the quality of his recommendations to institutional investors. He holds a Ph.D. in biochemistry.

Recent Articles about Sernova Biotherapeutics Inc.

FDA OKs Trial of Cell Reservoir in Thyroid Disease 03/10/2025

In this Phase 1 study, post-thyroidectomy patients will be treated with their own thyroid cells via this implantable delivery device, noted a Leede Financial Inc. report.

Biotherapeutic Co. Offers Potential Curative Alternative For Thyroid Disease 02/04/2025

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently filed a new IND for Cell Pouch in thyroid disease. Read on to see what rating and target price Leede Financial Inc. gave this company.

Opportunity Arises for Co. With Cell Pouch 11/12/2024

This medical device owner could team up with a biotech firm that just prioritized its diabetes program, noted a Leede Financial Inc. report.

Co's. Cell Pouch Performs Well in Study 09/16/2024

Data show the device keeps the incorporated therapeutic cells alive and functioning for at least five years, noted a Leede Financial Inc. report.